Iqvia reports Q3 adjusted EPS $3.00, consensus $2.98

Reports Q3 revenue $4.1B, consensus $4.08B. “IQVIA (IQV) delivered a strong quarter with revenue and profit towards the high-end of our guide, and record free cash flow generation,” said Ari Bousbib, chairman and CEO of Iqvia. “R&DS continued to perform well, with strong demand across all customer segments and improved client decision timelines leading to 13 percent growth in net bookings year-over-year. TAS delivered solid results despite a tougher year-over-year comparison, driven by ongoing momentum from drug launches and the strength of our broader commercial portfolio. With continued execution across the business and healthy demand indicators, such as RFP growth accelerating to 20 percent year-over-year, we remain confident in our ability to sustain our top and bottom-line growth performance.”